Official Title
An Open-Label, Multi-Center Patient Access Program of Olaratumab for the Treatment of Soft Tissue Sarcoma
Brief Summary

The purpose of this study is to continue to provide olaratumab to eligible patients who are currently receiving olaratumab commercially for the treatment of soft tissue sarcoma (STS).

Available
Individual Patients
Soft Tissue Sarcoma

Drug: Olaratumab
Administered intravenously (IV)
Other Name: LY3012207

Eligibility Criteria

Inclusion Criteria:

- Are currently receiving olaratumab and who, in consultation with their treating physician, want to continue their course of therapy.

- Have metastatic or locally advanced unresectable soft tissue sarcoma not amenable to curative treatment with surgery or radiotherapy.

- Have given written informed consent.

- Have an absolute neutrophil count (ANC) ≥1,000/microliter.

- Females of childbearing potential and males must agree to use highly effective contraceptive precautions during treatment with olaratumab and up to 3 months following the last dose of olaratumab. A highly effective method of birth control is defined as one that results in a low failure rate (that is,

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years
Countries
Austria
Brazil
Canada
Cyprus
Hungary
India
Italy
Korea, Republic of
Spain
United Kingdom
United States
Locations

Ironwood Cancer & Research Centers
Glendale, Arizona, 85306

Available

Contact: 480-324-5262

Investigator: Elisa T Bomgaars

The Angeles Clinic & Research Institute
Los Angeles, California, 90025

Available

Contact: 310-231-2118

Investigator: Lawrence Piro

Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, 90027

Available

Contact: 323-783-9013

Investigator: Karen W Kwan

Kaiser Permanente West Los Angeles
Los Angeles, California, 90034

Available

Contact: 323-857-2713

Investigator: Cannon Milani

Kaiser Permanente Moreno Valley
Moreno Valley, California, 92555

Available

Contact: 626-564-3506

Investigator: Vishal Ranpura

University of Colorado Health Hospital
Aurora, Colorado, 80045

Available

Contact: 720-848-0300

Investigator: Victor Villalobos

UCHealth Cancer Center
Fort Collins, Colorado, 80528

Available

Contact: 970-297-6150

Investigator: Diana Medgyesy

Baptist MD Anderson Cancer Center
Jacksonville, Florida, 32207

Available

Contact: 904-202-7300

Investigator: William Hammond

Mayo Clinic-Jacksonville
Jacksonville, Florida, 32224

Available

Contact: 904-953-2000

Investigator: Steven Attia

Ocala Oncology, P.A.
Ocala, Florida, 34474

Available

Investigator: Ketan D Doshi

Florida Cancer Specialists
Orlando, Florida, 32804

Available

Contact: 407-898-5452

Investigator: Yaman Suleiman

Orlando Health UF Health Cancer Center
Orlando, Florida, 32806

Available

Investigator: Thomas Samuel Sajeve

Florida Cancer Specialists
Sarasota, Florida, 34236

Available

Investigator: Caryn L Silver

Oncology & Hematology Associates
Tamarac, Florida, 33321

Available

Contact: 954-726-0035

Investigator: Sumit sawhney

Northside Hospital
Athens, Georgia, 30606

Available

Contact: 7063694478x5936

Investigator: Ali M Sayed

Tift Regional Health System Anita Stewart Oncology Center
Tifton, Georgia, 31794

Available

Contact: 229-382-7120

Investigator: James E Milner

Beacon Cancer Care
Coeur d'Alene, Idaho, 83814

Available

Contact: 208-755-2804

Investigator: Brian Samuels

Rush University Medical Center
Chicago, Illinois, 60612

Available

Contact: 312-942-5904

Investigator: Marta Batus

Illinois CancerCare
Peoria, Illinois, 61615

Available

Contact: 309-243-3000

Investigator: Nguyet A Le-Lindqwister

James Graham Brown Cancer Center
Louisville, Kentucky, 40202

Available

Contact: 502-852-2891

Investigator: Vivek Sharma

Hematology Oncology Clinic
Baton Rouge, Louisiana, 70809

Available

Contact: 225-767-0822

Investigator: Gerald Miletello

Alton Ochsner Medical Center
New Orleans, Louisiana, 70121

Available

Contact: 504-376-3863

Investigator: Marc R Matrana

University of Maryland, Baltimore
Baltimore, Maryland, 21201

Available

Contact: 410-328-2703

Investigator: Amin Benyounes

SKCCC at Johns Hopkins
Baltimore, Maryland, 21287

Available

Contact: 410-614-1361

Investigator: Stephanie Gaillard

Baltimore Washington Health Services
Glen Burnie, Maryland, 21061

Available

Contact: 410-553-8360

Investigator: Harvinder Singh

University of Massachusetts Medical Center
Worcester, Massachusetts, 01655

Available

Contact: 505-856-0056

Investigator: William Walsh

Henry Ford Macomb Hospital
Clinton Township, Michigan, 48038

Available

Contact: 586-263-2269

Investigator: Malathy Kilaru

Cancer & Hematology Centers of Western Michigan
Grand Rapids, Michigan, 49503

Available

Contact: 616-954-9800

Investigator: Judy Tsai

St. Luke's Hospital of Duluth
Duluth, Minnesota, 55805

Available

Contact: 218-249-2567

Investigator: Homam Alkaied

Masonic Cancer Center, University
Minneapolis, Minnesota, 55455

Available

Investigator: Domingo Musibay Evidio

Jackson Oncology Associates PLLC
Jackson, Mississippi, 39202-2002

Available

Contact: 601-355-2485

Investigator: Justin T Baker

University of Mississippi Medical Center
Jackson, Mississippi, 39216

Available

Investigator: Mildred Ridgway

County Oncologist, Inc.
Saint Louis, Missouri, 63136

Available

Contact: 314-355-8200

Investigator: Juan O Carden

Cooper Hospital University Medical Center
Camden, New Jersey, 08103

Available

Contact: 856-735-6289

Investigator: Polina Khrizman

Regional Cancer Care Associates, LLC
East Brunswick, New Jersey, 08816

Available

Contact: 732-390-7750

Investigator: MICHAEL J. NISSENBLATT

Hudson Valley Cancer Center
Fishkill, New York, 12524

Available

Contact: 845-896-8510

Investigator: Julia A Schaefer-Cutillo

SUNY Upstate Medical University
Syracuse, New York, 13210

Available

Contact: 315-464-8230

Investigator: Seth Rahul

SUNY Upstate Medical University
Syracuse, New York, 13210

Available

Contact: 315-464-8230

Investigator: Poiesz Bernard

East Carolina School of Medicine
Greenville, North Carolina, 27834

Available

Contact: 252-756-5388

Investigator: DARLA LILES

Aultman Medical Group Hematology & Oncology
Canton, Ohio, 44710

Available

Investigator: Shruti Trehan

University of Cincinnati Cancer Institute
Cincinnati, Ohio, 45219

Available

Contact: 513-584-6373

Investigator: Amanda L Jackson

Cleveland Clinic Foundation
Cleveland, Ohio, 44195

Available

Contact: 216-444-1128

Investigator: Dale Shepard

The James Cancer Hospital
Columbus, Ohio, 43210

Available

Contact: 614-685-7377

Investigator: Gabriel R Tinoco

Steward Sharon Regional Cancer Center
Hermitage, Pennsylvania, 16148

Available

Contact: 724-983-5900

Investigator: Mukhtar O Hassan

Abramson Cancer Center at Pennsylvania Hospital
Philadelphia, Pennsylvania, 19106

Available

Contact: 215-829-7089

Investigator: Lee Hartner

The West Clinic
Germantown, Tennessee, 38138

Available

Contact: 901-683-0055

Investigator: David C Portnoy

Tennessee Oncology PLLC
Hixson, Tennessee, 37343

Available

Contact: 4238760336

Investigator: Michael Anthony Stipanov

UVAHS Emily Couric Clin Cancer Ctr
Charlottesville, Virginia, 22903

Available

Contact: 434-924-9333

Investigator: Leigh Cantrell

Kaiser Permanente of WA
Olympia, Washington, 98506

Available

Contact: 360-923-7000

Investigator: Carolyn A. Wild

Harrison HealthPartners Hematology
Poulsbo, Washington, 98370

Available

Investigator: Toni Roberts

Seattle Integrative Cancer Center
Renton, Washington, 98360

Available

Contact: 206-588-1722

Investigator: Naixi Chen

Mon Health Medical Center
Morgantown, West Virginia, 26505

Available

Contact: 304-285-3870

Investigator: William C McBee

SSM Health Cancer Care Center
Madison, Wisconsin, 53717

Available

Contact: 608-410-2700

Investigator: Lisa Lepeak

West Allis Memorial Hospital
West Allis, Wisconsin, 53227

Available

Investigator: Elizabeth Dickson

Contacts

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559
clinicaltrials.gov@lilly.com

Eli Lilly and Company
NCT Number
MeSH Terms
Sarcoma
Olaratumab